Masri, A., Sherrid, M. V., Choudhury, L., Garcia-Pavia, P., Kramer, C. M., Barriales-Villa, R., … FOREST-HCM Investigators. (2025). Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM. J Card Fail. https://doi.org/10.1016/j.cardfail.2025.09.016

Masri, Ahmad, Mark V. Sherrid, Lubna Choudhury, Pablo Garcia-Pavia, Christopher M. Kramer, Roberto Barriales-Villa, Robert M. Cooper, et al. “Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM.” J Card Fail, September 28, 2025. https://doi.org/10.1016/j.cardfail.2025.09.016.

Masri A, Sherrid MV, Choudhury L, Garcia-Pavia P, Kramer CM, Barriales-Villa R, et al. Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM. J Card Fail. 2025 Sep 28;

Masri, Ahmad, et al. “Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM.” J Card Fail, Sept. 2025. Pubmed, doi:10.1016/j.cardfail.2025.09.016.

Masri A, Sherrid MV, Choudhury L, Garcia-Pavia P, Kramer CM, Barriales-Villa R, Cooper RM, Elliott PM, Hegde SM, Maron MS, Nassif ME, Oreziak A, Owens AT, Solomon SD, Tower-Rader A, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Melloni C, Simkins T, Wai J, Saberi S, FOREST-HCM Investigators. Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM. J Card Fail. 2025 Sep 28;